

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 24, 2025

Anti-TBX19 Antibody

RRID:AB_2732209

Type: Antibody

Proper Citation

(Atlas Antibodies Cat# HPA072686, RRID:AB_2732209)

Antibody Information

URL: http://antibodyregistry.org/AB_2732209

Proper Citation: (Atlas Antibodies Cat# HPA072686, RRID:AB_2732209)

Target Antigen: TBX19

Host Organism: rabbit

Clonality: unknown

Comments: Originating manufacturer of this product. Applications: IHC. Immunogen: Recombinant Protein Epitope Signature Tag (PrEST).

Antibody Name: Anti-TBX19 Antibody

Description: This unknown targets TBX19

Target Organism: human

Antibody ID: AB_2732209

Vendor: Atlas Antibodies

Catalog Number: HPA072686

Record Creation Time: 20231110T033610+0000

Record Last Update: 20240725T083032+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas
<https://www.proteinatlas.org/search/HPA072686>

No alerts have been found for Anti-TBX19 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Morita S, et al. (2024) Profiling of Unfolded Protein Response Markers and Effect of IRE1?-specific Inhibitor in Pituitary Neuroendocrine Tumor. *Endocrinology*, 165(4).

Hallén T, et al. (2023) Proteomic profiles associated with postsurgical progression in non-functioning pituitary adenomas. *The Journal of clinical endocrinology and metabolism*.

Taguchi A, et al. (2023) Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype. *Neurosurgical review*, 46(1), 317.

Hallén T, et al. (2022) Genome-wide DNA Methylation Differences in Nonfunctioning Pituitary Adenomas With and Without Postsurgical Progression. *The Journal of clinical endocrinology and metabolism*, 107(8), 2318.

Hickman RA, et al. (2021) Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway. *Neuropathology and applied neurobiology*, 47(3), 415.